• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    false --12-31 0001293818 0001293818 2026-02-23 2026-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    February 23, 2026
    Date of Report (date of earliest event reported)

     

     

     

    CapForce Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   001-37367   06-1614015
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification Number)

     

    23219 Stringtown Road, Suite 300
    Clarksburg, MD 20871
    (Address of principal executive offices)(Zip code)

     

    (240) 813-1260
    (Registrant’s telephone number, including area code)

     

    OpGen, Inc.
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   OPGN   OTC Markets Group, Inc.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    At the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of CapForce Inc. (the “Company”) approved the Company’s 2026 Incentive Compensation Plan (the “2026 Plan”). The 2026 Plan was previously approved by the Board of Directors (the “Board”) of the Company, subject to stockholder approval, on January 9, 2026. The 2026 Plan became effective on February 23, 2026 following receipt of stockholder approval at the Annual Meeting.

     

    The total number of shares of stock reserved and available for distribution under the 2026 Plan is 1,000,000 shares. In the event of any stock dividend, stock split, reverse stock split, share combination, recapitalization, merger, consolidation, spin-off, split-up, reorganization, rights offering, liquidation, or any similar change event of or by our Company, appropriate adjustments will be made to the shares subject to the 2026 Plan and to any outstanding awards.

     

    The 2026 Plan includes an evergreen provision providing for an automatic annual increase in the shares of common stock available for issuance under the 2026 Plan over the next 10 years in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. Pursuant to the evergreen provision, the number of shares available for issuance under the 2026 Plan shall automatically increase on January 1st of each year for a period of 9 years, commencing on January 1, 2027 and ending on (and including) January 1, 2036, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, provided that the Board of Directors may decide, prior to the first day of any calendar year, that there shall be no increase in the shares available for issuance under the 2026 Plan for such calendar year or that the increase shall be a lesser number of shares than otherwise provided under the evergreen provision.

     

    The material terms of the 2026 Plan are described in “Proposal No. 2 – Approval of the 2026 Equity Incentive Plan” the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) on February 6, 2026, which information is incorporated herein by reference. Such information and the foregoing description of the 2026 Plan do not purport to be complete and are qualified in their entirety by reference to the full text of the 2026 Plan, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    At the Annual Meeting, the stockholders of the Company also approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), pursuant to the Name Change Proposal (as defined below) providing for a change in the Company’s corporate name from OpGen, Inc. to CapForce Inc. In connection with the name change, the Company expects to change its ticker symbol to “CFOR.”

     

    The change in name of the Company and the filing of the Amendment will not affect the validity or transferability of any outstanding shares of common stock, and stockholders will not be required to exchange outstanding certificates for new share certificates.

     

    Following the approval of the Name Change Proposal at the Annual Meeting, the Company filed the Amendment with the Secretary of State of the State of Delaware on February 27, 2026. Except for the change of name of the Company, the Amendment does not make any other changes to the Company’s Certificate of Incorporation. In connection with the foregoing, the Company also amended and restated its Amended and Restated Bylaws, as amended (the “Bylaws”), to reflect the change in the Company’s name.

     

    The foregoing description of the Amendment and Bylaws do not purport to be complete and are qualified in their entirety by reference to the full text of the form of the Amendment and the Bylaws, which are filed as Exhibits 3.1, and 3.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

     

    1

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On February 23, 2026, the Company held its Annual Meeting. The Company’s stockholders voted on the proposals listed below, each of which was described in the Company’s proxy statement for the Annual Meeting as filed by the Company with the Securities and Exchange Commission on February 6, 2026. As of January 5, 2026, the record date for the Annual Meeting, shares of the Company’s capital stock representing 10,210,511 votes were outstanding. At the Annual Meeting, shares of the Company’s capital stock representing 8,344,457 votes were represented in person or by proxy. The following is a summary of the voting results for the proposals voted upon at the Annual Meeting:

     

    1. Proposal No. 1 – Election of Directors. Proposal No. 1 was the election of the following named persons to serve as directors of the Company for a one-year term or until their successors are elected and qualified. The votes cast were as follows:

     

    Nominee  For  Against  Abstained or Withheld
    Victor Chua Kok Hoe  8,336,639  6,700  1,118
    John Tan Honjian  8,336,650  6,689  1,118
    Ken Lim Zhao Qi  8,336,646  6,693  1,118
    Ethan Low Yu Jie  8,336,649  6,690  1,118
    Constance Wong Poh Yin  8,335,550  7,789  1,118

     

    Based on the foregoing vote, the five nominees listed above were elected to serve on the Board. There were no additional director nominations brought before the meeting.

     

    2. Proposal No. 2 – 2026 Equity Incentive Plan Proposal. Proposal No. 2 was to approve the 2026 Equity Incentive Plan (the “2026 Equity Incentive Plan Proposal”). The results of the vote were as follows:

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,299,282  8,808  36,367  N/A

     

    Based on the foregoing vote, the 2026 Equity Incentive Plan Proposal was approved.

     

    3. Proposal No. 3 – Warrant Exercise Proposal. Proposal No. 3 was to approve the issuance of 889,274 shares of the Company’s common stock upon the exercise of common stock purchase warrants issued in connection with the Company’s best efforts public offering that closed on May 4, 2023, as contemplated by Nasdaq listing rules (the “Warrant Exercise Proposal”). The results of the vote were as follows:

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,335,871  7,480  1,106  N/A

     

    Based on the foregoing vote, the Warrant Exercise Proposal was approved.

     

    4. Proposal No. 4 – Ratification of the Issuance of Certain Shares of Common Stock. Proposal No. 4 was to ratify the sale and issuance of certain shares of common stock of the Company to AEI Capital, Ltd., our controlling stockholder, for the purpose of exempting such sales and issuances from Section 16(b) under the Exchange Act pursuant to Rule 16b-3(d)(2) thereunder (the “Share Sale and Issuance Ratification Proposal”).

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,334,836  8,809  812  N/A

     

    2

     

     

    Based on the foregoing vote, the Share Sale and Issuance Ratification Proposal was approved.

     

    5. Proposal No. 5 – Name Change Proposal. Proposal No. 5 was to approve the change of the name of the Company from “OpGen, Inc.” to “CapForce Inc.” (the “Name Change Proposal”). The results of the vote were as follows:

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,333,795  9,063  1,599  N/A

     

    Based on the foregoing vote, the Name Change Proposal was approved.

     

    6. Proposal No. 6 – Say-on-Pay Advisory Vote. Proposal No. 6 was to approve, on an advisory basis, the compensation paid to the Company’s named executive officers (the “Say-on-Pay Advisory Vote”), as disclosed in the compensation discussion and analysis, the compensation tables, and any related material contained in the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting filed by the Company with the Securities and Exchange Commission on February 6, 2026.

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,299,141  8,640  36,676  N/A

     

    Based on the foregoing vote, the Say-on-Pay Advisory Vote was approved.

     

    7. Proposal No. 7 – Ratification of Appointment of Independent Accounting Firm. Proposal No. 7 was to ratify the appointment of Beckles & Co., Inc. to serve as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025. The results of the vote were as follows:

     

    Votes For  Votes Against  Abstained or Withheld  Broker Non-Votes
    8,335,053  6,216  3,188  N/A

     

    Based on the foregoing vote, the ratification of Beckles & Co., Inc. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved.

     

    Item 7.01 Regulation FD Disclosure

     

    On February 27, 2026, the Company issued a press release announcing the change of the Company’s name. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

     

    3

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, filed with the Secretary of State of the State of Delaware on February 27, 2026.
    3.2   Amended and Restated Bylaws of CapForce Inc., as effective February 27, 2026.
    10.1   CapForce Inc. 2026 Incentive Compensation Plan, effective February 23, 2026.
    99.1   Press Release dated February 27, 2026.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: February 27, 2026 CapForce Inc.
       
      By:

    /s/ Christian-Laurent Benoit Bonte

        Name: Christian-Laurent Benoit Bonte
        Title: Chief Executive Officer

     

    5

    Get the next $OPGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)

    3 - OPGEN INC (0001293818) (Issuer)

    12/10/25 9:08:45 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    4/30/25 4:32:10 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    12/10/24 12:32:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    10/8/24 6:51:09 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

    ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

    5/24/24 4:04:59 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Announced 1-for-10 Reverse Stock Split

    ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

    5/16/24 7:00:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright resumed coverage on OpGen with a new price target

    HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

    3/15/21 7:37:07 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/8/21 8:22:12 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/2/21 10:53:18 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by OpGen Inc.

    DEF 14A - OPGEN INC (0001293818) (Filer)

    2/6/26 1:05:05 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by OpGen Inc.

    PRE 14A - OPGEN INC (0001293818) (Filer)

    1/26/26 5:25:46 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Financials

    Live finance-specific insights

    View All

    OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

    8/10/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

    ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

    8/3/23 7:30:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

    5/15/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OpGen Inc.

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    8/1/24 5:25:39 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/25/24 5:43:11 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/8/24 4:05:12 PM ET
    $OPGN
    Medical Specialities
    Health Care